

CITATION REPORT

List of articles citing

Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma

DOI: 10.1002/bmc.4365

Biomedical Chromatography, 2018, 32, e4365.

Source: <https://exaly.com/paper-pdf/71661305/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats. <i>Molecules</i> , 2018 , 23,	4.8	8
15	Simultaneous determination of aflutininib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 176, 112735	3.5	7
14	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced -Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. <i>Biomolecules</i> , 2019 , 9,	5.9	39
13	Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1136, 121851	3.2	17
12	Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results. <i>Biomedical Chromatography</i> , 2020 , 34, e4771	1.7	2
11	Tandem mass spectrometry of small-molecule signal transduction inhibitors: Accurate-m/z data to adapt structure proposals of product ions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 195, 113864	3.5	1
10	Interpretation of MS/MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites. <i>International Journal of Mass Spectrometry</i> , 2021 , 464, 116559	1.9	1
9	Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. <i>Biomedical Chromatography</i> , 2021 , 35, e5224	1.7	0
8	Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1162, 122466	3.2	1
7	An UPLC-MS/MS Method for Determination of Osimertinib in Rat Plasma: Application to Investigating the Effect of Ginsenoside Rg3 on the Pharmacokinetics of Osimertinib. <i>International Journal of Analytical Chemistry</i> , 2020 , 2020, 8814214	1.4	2
6	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. <i>Molecular Cancer</i> , 2022 , 21, 61	42.1	0
5	The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 794931	5.6	0
4	Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022 , 1197, 123231	3.2	0
3	Simultaneous determination of almonertinib and its active metabolite HAS-719 in human plasma by LC-MS/MS: Evaluation of pharmacokinetic interactions.. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022 , 1197, 123231	3.2	0
2	Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to the simultaneous determination of osimertinib and its active metabolite in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022 , 202, 115555	3.5	0
1	Simultaneous and Rapid Determination of Plasma Concentrations of Four Tyrosine Kinase Inhibitors Using Liquid Chromatography/Tandem Mass Spectrometry in Patients with Non-Small Cell Lung Cancer. 2023 ,		0